BlueWillow Biologics
David M. Stout has served as a top-level pharmaceutical executive, both nationally and internationally, for the past 30 years. His most recent position was President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals. In this capacity, he led all global commercial activities, global manufacturing, and all vaccine-related activities for the company, including research and development. Additionally, Mr. Stout directed the corporate pandemic flu preparedness program – an international effort that supports governments, health authorities, and company employees around the world in responding to a global influenza pandemic.
Prior to his tenure at GSK, Mr. Stout served as President of SmithKline Beecham’s North American pharmaceutical business, launching two major products and two sales force expansions. His pharmaceutical career began at Warner-Lambert Pharmaceutical Company and continued at Schering-Plough Corporation, where he served in numerous positions, including President of Schering Laboratories.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
BlueWillow Biologics
BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. The platform employs novel oil-in-water nano-droplets for products administered to the skin and nose. The company was founded as a spin-off from the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation, NIH and DOD contracts, BlueWillow’s technology has been advanced significantly in recent years yielding several therapies in development.